弥合差距：实验室自建检测在临床毒理学中的关键作用。
Bridging the gap: The critical role of laboratory developed tests in clinical toxicology.
作者信息
Noguez Jaime H, Koch Christopher D
机构信息
Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.
Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
出版信息
J Mass Spectrom Adv Clin Lab. 2023 Feb 22;28:70-74. doi: 10.1016/j.jmsacl.2023.02.007. eCollection 2023 Apr.
Abstract
•Toxicology testing provides valuable information for patient management.•Current in vitro diagnostics (IVDs) are unable to meet all clinical needs.•Lab-developed tests (LDTs) in toxicology can be used to close clinical care gaps.•LDTs in clinical toxicology are almost exclusively mass spectrometry-based methods.
摘要
•毒理学检测为患者管理提供有价值的信息。
•当前的体外诊断（IVD）无法满足所有临床需求。
•毒理学中的实验室开发检测（LDT）可用于弥合临床护理差距。
•临床毒理学中的LDT几乎完全是基于质谱的方法。
相似文献
1
Bridging the gap: The critical role of laboratory developed tests in clinical toxicology.弥合差距：实验室自建检测在临床毒理学中的关键作用。
J Mass Spectrom Adv Clin Lab. 2023 Feb 22;28:70-74. doi: 10.1016/j.jmsacl.2023.02.007. eCollection 2023 Apr.
2
Laboratory-Developed Tests: Design of a Regulatory Strategy in Compliance with the International State-of-the-Art and the Regulation (EU) 2017/746 (EU IVDR [In Vitro Diagnostic Medical Device Regulation]).实验室自建检测方法：符合国际最新技术水平及欧盟法规（EU）2017/746（欧盟体外诊断医疗器械法规）的监管策略设计
Ther Innov Regul Sci. 2022 Jan;56(1):47-64. doi: 10.1007/s43441-021-00323-7. Epub 2021 Jul 21.
3
Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT).使用体外诊断（IVD）与实验室自建检测方法（LDT）检测非小细胞肺癌（NSCLC）中PD-L1的成本效益分析
Oncol Ther. 2022 Dec;10(2):391-409. doi: 10.1007/s40487-022-00197-1. Epub 2022 May 13.
4
The new IVD Regulation 2017/746: a case study at a large university hospital laboratory in Belgium demonstrates the need for clarification on the degrees of freedom laboratories have to use lab-developed tests to improve patient care.2017/746 号新体外诊断法规：比利时一家大型大学医院实验室的案例研究表明，有必要明确实验室在使用实验室自建检测以改善患者护理方面的自由度。
Clin Chem Lab Med. 2020 Jul 21;59(1):101-106. doi: 10.1515/cclm-2020-0804.
5
Laboratory-Developed Tests: A Legislative and Regulatory Review.实验室自建检测方法：立法与监管审查
Clin Chem. 2017 Oct;63(10):1575-1584. doi: 10.1373/clinchem.2017.275164. Epub 2017 Jul 7.
6
Impact of VALID Act implementation on mass spectrometry-based clinical proteomic laboratory developed tests.《有效法案》的实施对基于质谱的临床蛋白质组学实验室自建检测的影响
J Mass Spectrom Adv Clin Lab. 2023 Feb 13;28:30-34. doi: 10.1016/j.jmsacl.2023.02.001. eCollection 2023 Apr.
7
Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.日本伴随诊断的发展前景及鼓励个性化医疗的监管环境。
Breast Cancer. 2016 Jan;23(1):19-23. doi: 10.1007/s12282-015-0586-y. Epub 2015 Jan 22.
8
The Panther Fusion System with Open Access Functionality for Laboratory-Developed Tests for Influenza A Virus Subtyping.带有实验室开发的流感 A 病毒分型检测的开放访问功能的 Panther Fusion 系统。
J Clin Microbiol. 2020 May 26;58(6). doi: 10.1128/JCM.00188-20.
9
Regulation of Laboratory-Developed Tests.实验室自建检测的监管。
Am J Clin Pathol. 2019 Jul 5;152(2):122-131. doi: 10.1093/ajcp/aqz096.
10
Metabolomic Laboratory-Developed Tests: Current Status and Perspectives.代谢组学实验室自主研发的检测方法：现状与展望。
Metabolites. 2021 Jun 26;11(7):423. doi: 10.3390/metabo11070423.
引用本文的文献
1
Definitive urine drug testing in emergency medicine: Recreational and psychiatric drug findings.急诊医学中的确定性尿液药物检测：娱乐性和精神类药物检测结果
J Mass Spectrom Adv Clin Lab. 2025 Apr 23;37:16-27. doi: 10.1016/j.jmsacl.2025.04.008. eCollection 2025 Aug.
本文引用的文献
1
Development of a Machine Learning Algorithm for Drug Screening Analysis on High-Resolution UPLC-MSE/QTOF Mass Spectrometry.用于高分辨率超高效液相色谱-串联质谱/四极杆飞行时间质谱药物筛选分析的机器学习算法开发
J Appl Lab Med. 2023 Jan 4;8(1):53-66. doi: 10.1093/jalm/jfac100.
2
Anabasine and Anatabine Exposure Attributable to Cigarette Smoking: National Health and Nutrition Examination Survey (NHANES) 2013-2014.安纳巴宾和去甲烟碱暴露归因于吸烟：2013-2014 年国家健康和营养调查（NHANES）。
Int J Environ Res Public Health. 2022 Aug 8;19(15):9744. doi: 10.3390/ijerph19159744.
3
The Verifying Accurate Leading-edge IVCT Development Act: Potential impact on diagnostic testing in the United States.《验证准确前沿IVCT发展法案》：对美国诊断检测的潜在影响。
Int J Lab Hematol. 2022 Sep;44 Suppl 1:9-10. doi: 10.1111/ijlh.13865. Epub 2022 May 10.
4
Urine toxicology screening by liquid chromatography time-of-flight mass spectrometry in a quaternary hospital setting.在一所四级医院环境中，采用液相色谱飞行时间质谱法进行尿液毒理学筛查。
Clin Biochem. 2021 Sep;95:66-72. doi: 10.1016/j.clinbiochem.2021.05.004. Epub 2021 May 12.
5
FDA-Cleared versus Laboratory-Developed Tests: Why Start from Scratch When Kits Are Available?美国食品药品监督管理局（FDA）批准的检测与实验室自行开发的检测：有试剂盒可用时为何要从头开始？
J Appl Lab Med. 2017 Jul 1;2(1):130-131. doi: 10.1373/jalm.2016.021832.
6
Evaluation of the first immunosuppressive drug assay available on a fully automated LC-MS/MS-based clinical analyzer suggests a new era in laboratory medicine.基于完全自动化 LC-MS/MS 的临床分析器上首个免疫抑制药物检测试剂盒的评估表明实验室医学进入了一个新时代。
Clin Chem Lab Med. 2020 Oct 19;59(5):913-920. doi: 10.1515/cclm-2020-0848. Print 2021 Apr 27.
7
Throughput Considerations for a Sample-Multiplexed LC-MS/MS Assay: Is the Ability to Double the Injection Throughput Always a Time Saver?
Clin Chem. 2020 Sep 1;66(9):1125-1127. doi: 10.1093/clinchem/hvaa171.
8
Urinary Buprenorphine, Norbuprenorphine and Naloxone Concentrations and Ratios: Review and Potential Clinical Implications.尿中丁丙诺啡、去甲丁丙诺啡和纳洛酮浓度及其比值：综述及潜在临床意义。
J Addict Med. 2020 Dec;14(6):e344-e349. doi: 10.1097/ADM.0000000000000676.
9
Regional Differences in the Drugs Most Frequently Involved in Drug Overdose Deaths: United States, 2017.2017年美国药物过量死亡中最常涉及药物的地区差异
Natl Vital Stat Rep. 2019 Oct;68(12):1-16.
10
Mass spectrometry and total laboratory automation: opportunities and drawbacks.质谱和全实验室自动化：机遇与挑战。
Clin Chem Lab Med. 2020 Jun 25;58(6):994-1001. doi: 10.1515/cclm-2019-0723.
Zotero 插件